{"organizations": [], "uuid": "21232552eb8a363180f20d794c2f0fc30d816488", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180202.html", "section_title": "Archive News &amp; Video for Friday, 02 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-yichang-hec-changjiang-pharmaceuti/brief-yichang-hec-changjiang-pharmaceutical-co-expects-fy-profit-attributable-to-rise-at-least-70-pct-idUSFWN1PS0K9", "country": "US", "domain_rank": 408, "title": "BRIEF-Yichang Hec Changjiang Pharmaceutical Co ‍Expects FY​ Profit Attributable To Rise At Least 70 Pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.93, "site_type": "news", "published": "2018-02-02T16:39:00.000+02:00", "replies_count": 0, "uuid": "21232552eb8a363180f20d794c2f0fc30d816488"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-yichang-hec-changjiang-pharmaceuti/brief-yichang-hec-changjiang-pharmaceutical-co-expects-fy-profit-attributable-to-rise-at-least-70-pct-idUSFWN1PS0K9", "ord_in_thread": 0, "title": "BRIEF-Yichang Hec Changjiang Pharmaceutical Co ‍Expects FY​ Profit Attributable To Rise At Least 70 Pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-yichang hec changjiang pharmaceutical co", "sentiment": "negative"}, {"name": "yichang hec changjiang pharmaceutical co ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 2 (Reuters) - Yichang Hec Changjiang Pharmaceutical Co Ltd:\n* ‍EXPECTED THAT GROUP WILL RECORD A NO LESS THAN 70 PCT INCREASE IN ITS PROFIT ATTRIBUTABLE FOR FY​\n* EXPECTED RESULT DUE TO SIGNIFICANT INCREASE IN SALES VOLUME OF COMPANY‘S KEY PRODUCT KEWEI Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T16:39:00.000+02:00", "crawled": "2018-02-03T21:14:42.033+02:00", "highlightTitle": ""}